Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | HPN | P05981 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203002 | 1.00 | SYK (0.54) | SYKCDK2PORCNPLAUHPN | |
| SCHEMBL5241338 | 0.84 | SYK (0.50) | SYKPORCNPLAUHPNBACE1 | |
| SCHEMBL3554471 | 0.84 | SYK (0.50) | SYKPORCNPLAUHPNBACE1 | |
| SCHEMBL3550347 | 0.81 | SYK (0.49) | SYKCDK2PIK3C3BACE1CNR2 | |
| SCHEMBL13724767 | 0.81 | SYK (0.49) | SYKCDK2PIK3C3BACE1CNR2 | |
| SCHEMBL5201754 | 0.80 | PORCN (0.47) | SYKPORCNPLAUHPNBACE1 | |
| SCHEMBL3546921 | 0.80 | PORCN (0.47) | SYKPORCNPLAUHPNBACE1 | |
| SCHEMBL13723702 | 0.78 | SYK (0.50) | SYKCDK2PIK3C3BACE1CNR2 | |
| SCHEMBL3552676 | 0.74 | MAPT (0.50) | SYKALDH1A1MAPT | |
| SCHEMBL13105736 | 0.73 | SYK (0.51) | SYKPORCNBACE1CNR2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655652-B2 | 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | SYK 1700/4885CDK2 84/4885PORCN 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.